SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-040521
Filing Date
2021-08-05
Accepted
2021-08-05 16:21:00
Documents
14
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea145237-8k_nektarthera.htm   iXBRL 8-K 34856
2 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS SECOND QUARTER 2021 FINANCIAL ea145237ex99-1_nektarthera.htm EX-99.1 94333
3 GRAPHIC ex99-1_001.jpg GRAPHIC 6216
  Complete submission text file 0001213900-21-040521.txt   322107

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nktr-20210805.xsd EX-101.SCH 3018
5 XBRL LABEL FILE nktr-20210805_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE nktr-20210805_pre.xml EX-101.PRE 22354
7 EXTRACTED XBRL INSTANCE DOCUMENT ea145237-8k_nektarthera_htm.xml XML 3495
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 211148534
SIC: 2834 Pharmaceutical Preparations